Last Updated : December 9, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Botox | OnabotulinumtoxinA | Neurogenic detrusor overactivity | List with clinical criteria and/or conditions | Complete | ||
Botox | OnabotulinumtoxinA | Migraine | Do not list | Complete | ||
Botox | OnabotulinumtoxinA | Urinary incontinence | List with criteria/condition | Complete | ||
Braftovi | encorafenib | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Braftovi and Mektovi | encorafenib and binimetinib | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Brenzys | Etanercept | Rheumatoid arthritis, Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Breo Ellipta | Fluticasone furoate /vilanterol | Chronic Obstructive Pulmonary Disease (COPD) | List with criteria/condition | Complete | ||
Breo Ellipta | Fluticasone Furoate and Vilanterol (as trifenatate) | Asthma | List with clinical criteria and/or conditions | Complete | ||
Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | |||
Breo Ellipta | fluticasone furoate/vilanterol | Asthma | Withdrawn | |||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Active | |||
Breztri Aerosphere | budesonide/ glycopyrronium /formoterol fumarate | chronic obstructive pulmonary disease (COPD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
Brilinta | Ticagrelor | Acute coronary syndromes | Do not list | Complete | ||
Brilinta | ticagrelor | Prevention of atherothrombotic events with history of myocardial infarction | Reimburse with clinical criteria and/or conditions | Complete | ||
Brineura | cerliponase alfa | Neuronal Ceroid Lipofuscinosis Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Brivlera | Brivaracetam | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
Brukinsa | zanubrutinib | Chronic lymphocytic leukemia /small lymphocytic lymphoma. | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Relapsed or refractory follicular lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Brukinsa | zanubrutinib | Waldenström’s macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
BuTrans | Buprenorphine transdermal patch | Pain, moderate intensity persistent pain | Do not list | Complete |